Pedmark is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Pedmark is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand namePedmark
Authorized genericsodium thiosulfate
Regular genericsodium thiosulfate
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Pedmark?
The original
–
–

Brand nameThe maker’s card

Fennec HEARS Copay Program

Savings card from Fennec Pharmaceuticals

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on pedmark.com 

In the maker’s words

“If you have commercial or private health insurance: You may be eligible for a $0 copay savings program…”

From the maker’s offer on pedmark.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Pedmark itself, from the same company, sold without the brand name, and usually for less. For now Pedmark is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Limitations of Use:

The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.

Source: the FDA label for Pedmark (Fennec Pharmaceuticals Inc.), October 27, 2025. Full label on DailyMed 

Good to know